Pharmacy · March 13, 2012 · Drug Channels Institute, an HMP Global company
Rite Aid: Smart or Lucky?
Well, hit me on the head and call me shorty! Good ol’ Rite Aid (NYSE: RAD) is showing signs of life.
Same store pharmacy sales are growing, the company is getting a bit trimmer, debt is (slowly) being paid off, and the stock price has doubled since October.
They have a long way to go to achieve actual business health, but I see a low risk of outright bankruptcy. Rite-Aid’s $6+ billion debt load remains a big deterrent to any potential acquirer … unless Walgreen (NYSE: WAG) gets very, very desperate.
Read on for my take on their reanimation. What do you think: Are they lucky or smart?
GROWING
Rite Aid’s same store prescription revenue growth has historically lagged both CVS retail (NYSE: CVS) and Walgreen (NYSE: WAG). In 2011, same store growth turned positive. And in 2012, Rite Aid is way ahead of Walgreen. CVS no longer reports monthly data, but its quarterly growth remains above Rite Aid. (Click to enlarge the chart.)
- By finally closing underperforming stores, the overall average growth rate has improved. (See below.)
- Rite Aid is picking up Express Scripts customers who are leaving Walgreens. (This hypothesis appears consistent with the increase during the past 5 months.)
- Wellness+ is increasing prescription business.
SHRINKING
About two years ago in What's Next for Rite-Aid, I suggested that Rite Aid needed to drop 1,000 stores and focus on being a super-regional player.
Well, they are getting a bit smaller. They are dropping about 50 stores per quarter. Total store count is down by 475 since the 2007 Brooks/Eckerd deal. They can shrink faster if the commercial real estate market improves, because the company’s non-cancelable leases could have significant value for other retailers if rents are below market.
AND STILL BORROWING
Rite Aid’s mountain of debt remains a big problem, although its obligations continue to be pushed further into the future. Here’s a look at Rite Aid’s debt profile as of last November.
Don’t call it a comeback. They’ve been here for years.
Pharmacy




